Retatrutide · 39 amino acids

Retatrutide for Sleep Apnea: What the TRIUMPH-OSA Trials Found


Short answer: yes, retatrutide improved sleep apnea in two phase 3 trials, and by a lot. In results published in the New England Journal of Medicine and featured by Lilly at ObesityWeek on November 15, 2026, the two higher doses cut breathing interruptions by about 25 to 34 events per hour over 80 weeks, versus about 10 on placebo. Roughly 4 to 5 in 10 people on those doses ended with sleep apnea that was gone or mild. The honest part: retatrutide is still not approved for anything, and the lowest dose did not clear the statistical bar.

Key facts

What are the TRIUMPH-OSA trials?

Obstructive sleep apnea (OSA) is when your airway keeps collapsing during sleep, so breathing stops or goes shallow over and over. The score doctors use is the apnea-hypopnea index (AHI): the average number of those events per hour of sleep.

Lilly tested retatrutide, its once-weekly shot that acts on three hormone receptors (GIP, GLP-1 and glucagon), in two phase 3 trials built inside its larger TRIUMPH obesity trials. Both were randomized, double-blind and placebo-controlled, which is the strongest kind of evidence a drug gets before approval.

People got 4 mg, 9 mg or 12 mg of retatrutide or a placebo for 80 weeks. Per Healio, everyone started low and stepped up every 4 weeks, and 88% and 89% of participants finished the two trials. Lead author Ronald Grunstein of the Woolcock Institute of Medical Research in Sydney told Healio the group had both severe sleep apnea and severe obesity. On the diabetes trial he said: “No one really looked at that population before.”

New to the drug itself? Start with what retatrutide is.

How much did sleep apnea improve?

The main goal was the AHI change at 80 weeks on the 9 mg and 12 mg doses. Both doses hit it in both trials.

Result at 80 weeks 4 mg 9 mg 12 mg Placebo
AHI change, no diabetes (events/hour) -22.9 -34.3 -31.7 -9.9
AHI change, type 2 diabetes (events/hour) -19.2 -24.7 -25.4 -10.3
Apnea gone or mild, no diabetes not reported 51.6% 42.3% 12.5%
Apnea gone or mild, type 2 diabetes not reported 39.5% 38.9% 12.6%

“Gone or mild” is the trial’s own bar, per Healio: an AHI under 5, or 5 to 14 without daytime sleepiness (an Epworth Sleepiness Scale score of 10 or less).

Compared with placebo, that works out to about 24 and 22 fewer events an hour on the two higher doses in people without diabetes, and about 14 and 15 fewer in people with diabetes. When the researchers counted everyone who was randomized (intention to treat), the gaps barely moved: 24.7 and 22.5 without diabetes, 13.9 and 15.0 with it.

Worth noticing: more was not clearly better. Without diabetes, 9 mg landed slightly ahead of 12 mg.

Weight came down too: 12.5% to 22.2% across doses without diabetes and 12.1% to 18.5% with diabetes, versus 4.8% and 5.6% on placebo. Healio also reports larger improvements in blood pressure, cholesterol and hsCRP, a blood marker of inflammation, though the article gives no values for them.

Why Lilly’s own number is bigger

Lilly’s ObesityWeek release (Nov 14, 2026) says retatrutide reduced AHI “by up to an average of 36.1 events per hour (60.6%)” in TRIUMPH-1 and by up to 28.4 events per hour (48.1%) in TRIUMPH-2. Those are the same trials. The release does not say which dose or which counting method produced those figures, and it shows no placebo number next to them. The 36.1 figure goes back to Lilly’s announcement at the American Diabetes Association meeting in June 2026, per Sleep Review.

The NEJM numbers in the table above are the peer-reviewed ones, with the placebo arm shown. Those are the ones worth quoting.

How does it compare with Zepbound and Foundayo?

Nobody has tested these against each other for sleep apnea, so this is context, not a ranking.

One thing these trials do not settle is whether a drug can stand in for CPAP, the mask and machine that keeps the airway open. Grunstein told Healio he thinks medicines in this class could potentially replace CPAP for most patients, and that CPAP does not bring weight loss or the blood pressure drop these drugs seem to. That is his read of the field, not something these trials tested. The coverage we read does not report how many participants were using CPAP.

The fine print

Promising and unfinished can both be true:

When could retatrutide be available for sleep apnea?

Not soon, and not on a known date. Lilly said on Sept 29, 2026 that it plans to submit retatrutide to the FDA in Q1 2027. That release does not say which uses the first filing will cover, so a sleep apnea label is not confirmed. Sleep apnea is one of the conditions in the phase 3 program, alongside obesity, type 2 diabetes, knee osteoarthritis pain and others. Our retatrutide availability timeline tracks the filing.

Until then, retatrutide only reaches people through Lilly’s own channels, mainly clinical trials. Lilly’s wording is blunt: anyone purporting to sell retatrutide to consumers is breaking the law. Vials sold on the internet as retatrutide are not the trial drug, and nobody checks what is in them. Our legal status tracker covers where unapproved peptides stand.

What it means for you

If you snore hard, wake up tired or gave up on your CPAP, step one is the same as ever: a sleep study and a real diagnosis. If you have sleep apnea and obesity, an approved option already exists (Zepbound), and a licensed provider can tell you whether it fits, how it works alongside CPAP, and what the side effects look like for you. Retatrutide looks like a strong future option, especially at 9 mg and 12 mg, but it is not available yet, and waiting on it is not a treatment plan. For the joint side of the same trial program, see retatrutide for knee pain. The retatrutide profile has the evidence grade and current FDA status.

Sources

Educational content only, not medical advice. Retatrutide is investigational and not FDA-approved for sleep apnea or any other use as of Nov 20, 2026; talk to a licensed provider about diagnosis and treatment options.

← All articles